References
- Bociek R, Kuruvilla J, Pro B, et al. (2008). Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). J Clin Oncol 26:8507
- Campas-Moya C. (2009). Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today 45:787–95
- Crump M, Andreadis C, Assouline S, et al. (2008). Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol 26: Abstract 8528
- De Ruijter A, Van Gennip A, Caron H, et al. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–49
- European Medicines Agency (EMA). (2011). Guideline on bioanalytical method validation. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf [last accessed 3 Mar 2014]
- Fournel M, Bonfils C, Hou Y, et al. (2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7:759–68
- Gallinari P, Di Marco S, Jones P, et al. (2007). HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17:195–211
- Garcia-Manero G, Assouline S, Cortes J, et al. (2008). Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112:981–9
- Glaser KB, Li J, Staver MJ, et al. (2003). Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310:529–36
- Grant S, Easley C, Kirkpatrick P. (2007). Vorinostat. Nat Rev Drug Discov 6:21–2
- Hassig CA, Schreiber SL. (1997). Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol 1:300–8
- Hu E, Dul E, Sung C-M, et al. (2003). Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720–8
- Maiso P, Carvajal-Vergara X, Ocio EM, et al. (2006). The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66:5781–9
- Marks PA, Rifkind RA, Richon VM, et al. (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202
- McKinsey TA, Zhang CL, Olson EN. (2001). Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 11:497–504
- Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51
- Qian X, Ara G, Mills E, et al. (2008). Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 122:1400–10
- Siu LL, Pili R, Duran I, et al. (2008). Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 26:1940–7
- Turner BM. (2000). Histone acetylation and an epigenetic code. Bioessays 22:836–45
- US Food and Drug Administration. (2001). Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf [last accessed 3 Mar 2014]
- Wang Z, Zang C, Cui K, et al. (2009). Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138:1019–31
- Williams JS, Donahue SH, Gao H, Brummel CL. (2012). Universal LC-MS method for minimized carryover in a discovery bioanalytical setting. Bioanalysis 4:1025–37
- Younes A, Wedgwood A, McLaughlin P, et al. (2007). Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. Blood 110:2571
- Zhou N, Moradei O, Raeppel S, et al. (2008). Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino) methyl] benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem 51:4072–5